Akari Therapeutics

A Revolution in Treating Autoinflammatory & Orphan Diseases

Menu

Publications

  1. Eskandarpour M. et al: Allergic eye disease: Blocking LTB4/C5 in vivo suppressed disease and Th2 & Th9 cells, Allergy, October 2021. https://onlinelibrary.wiley.com/doi/10.1111/all.15128.

  2. Eskandarpour M,  Nunn MA, Weston-Davies WH, Calder VL. Immune-Mediated Retinal Vasculitis in Posterior Uveitis and Experimental Models: The Leukotriene (LT)B4-VEGF Axis. Cells. 2021 Feb. https://www.mdpi.com/2073-4409/10/2/396.

  3. Sezin T, … , Nunn MA, Sadik CD. Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight. 2019;4(15):e128239. https://doi.org/10.1172/jci.insight.128239.

  4. Goodship THJ, Pinto F, Weston-Davies WH, Silva J, Nishimura J,  Nunn MA, Mackie I, Machin SJ, Palm L, Pryce JW, Chiesa R, Amrolia P, Veys P. Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Advances. 2017 Jul;1(16).
  5. Pischke SE,  Gustavsen A, Orrem HL, Egge KH, Courivaud F, Fontenelle H, Despont A, Bongoni AK, Rieben R, Tønnessen TI,  Nunn MA, Scott H, Skulstad H, Barratt-Due A, Mollnes TE. Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function. Basic Res Cardiol. 2017 Mar.
  6. Kuhn N, Schmidt CQ, Schlapschy M, Skerra A. PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro. Bioconjugate Chemistry. 2016.
  7. Volk AL, Hu FJ, Berglund MM, Nordling E, Strömberg P, Uhlen M, Rockberg J. Stratification of responders towards eculizumab using a structural epitope mapping strategy. Scientific Reports. 2016 Aug.
  8. Jore MM, Johnson S, Sheppard D, Barber NM, Li YI, Nunn MA, Elmlund H, Lea SM. Structural basis for therapeutic inhibition of complement C5. Nature Structural and Molecular Biology. 2016 Mar.
  9. Skjeflo EW, Sagatun C, Dybwik K, Aam S, Urving SH, Nunn MA, Fure H, Lau C, Brekke OL, Huber-Lang M, Espevik T, Barratt-Due A, Nielsen EW, Mollnes TE.  Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis. Critical Care. 2015.
  10. Berends ET, Mohan S, Miellet WR, Ruyken M, Rooijakkers SH. Contribution of the complement Membrane Attack Complex to the bactericidal activity of human serum. Mol Immunol. 2015 Jun;65(2):328-35.
  11. Egge KH, Thorgersen EB, Pischke SE, Lindstad JK, Pharo A, Bongoni AK, Rieben R, Nunn MA, Barratt-Due A, Mollnes TE. Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14. Immunobiology. 2015 Aug;220(8):999-1005.
  12. Blom AM, Volokhina EB, Fransson V, Strömberg P, Berghard L, Viktorelius M, Mollnes TE, López-Trascasa M, van den Heuvel LP, Goodship TH, Marchbank KJ, Okroj M. A novel method for direct measurement of complement convertases activity in human serum. Clin Exp Immunol. 2014 Oct;178(1):142-53.
  13. Romay-Penabad Z, Carrera Marin AL, Willis R, Weston-Davies W, Machin S, Cohen H, Brasier A, Gonzalez EB. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus. 2014 Oct;23(12):1324-6.
  14. Huber-Lang M, Barratt-Due A, Pischke SE, Sandanger Ø, Nilsson PH, Nunn MA, Denk S, Gaus W, Espevik T, Mollnes TE. Double Blockade of CD14 and Complement C5 Abolishes the Cytokine Storm and improves Morbidity and Survival in Polymicrobial Sepsis in Mice. J Immunol. 2014 Jun 1;192(11):5324-31.
  15. Westwood J-P, Weston-Davies WH, Hillmen P, Richards SJ, Mackie IJ, Machin SJ and Prudo R. Coversin, a Small Protein Complement Inhibitor, is a Potential Novel Anti-thrombotic Agent. British Journal of Haematology, May 2014, 165, (Suppl.) 3
  16. Fluiter K1, Opperhuizen AL, Morgan BP, Baas F, Ramaglia V. Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. J Immunol. 2014 Mar 1;192(5):2339-48.
  17. Barratt-Due A, Thorgersen EB, Egge K, Pischke S, Sokolov A, Hellerud BC, Lindstad JK, Pharo A, Bongoni AK, Rieben R, Nunn M, Scott H, Mollnes TE. (2013). Combined inhibition of complement C5 and CD14 markedly attenuates inflammation, thrombogenicity and haemodynamic changes in porcine sepsis. J Immunol 191 (2): 812-27.
  18. Roversi P, Ryffel B, Togbe D, Maillet I, Teixeira M, Ahmat N, Paesen GC, Lissina O, Boland W, Ploss K, Caesar JJ, Leonhartsberger S, Lea SM, Nunn MA. (2013). Bifunctional lio]pocalin ameliorates murine immune complex –induced lung injury. J Biol Chem 288(26): 18789 -802.
  19. Garcia C.C., Weston-Davies W, Russo RC, Tavares LP, Rachid MA, Alves-Filho JC, Machado AV, Ryffel B, Nunn MA, Teixeira MM (2013). Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury. PLoS One 8(5): e64443.
  20. Barratt-Due A, Thorgersen EB, Lindstad JK, Pharo A, Lissina O, Lambris JD, Nunn MA, Mollnes TE. 2011. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J.Immunol. (2011 Nov) 1;187(9):4913-9. Epub 2011 Sep 30.
  21. Kaminski, H. J. (2007). Restoring balance at the neuromuscular junction. Neurology 69:629-630. (Editorial)
  22. Halstead, S. K., P. D. Humphreys, F. M. Zitman, J. Hamer, J. J. Plomp, and H. J. Willison. (2008). C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J Peripher Nerv Syst 13:228-235.
  23. Fredslund, F., N. S. Laursen, P. Roversi, L. Jenner, C. L. Oliveira, J. S. Pedersen, M. A. Nunn, S. M. Lea, R. Discipio, L. Sottrup-Jensen, and G. R. Andersen. (2008). Structure of and influence of a tick complement inhibitor on human complement component 5. Nature immunology 9:753-760.
  24. Soltys, J., L. L. Kusner, A. Young, C. Richmonds, D. Hatala, B. Gong, V. Shanmugavel, and H. J. Kaminski. (2009). Novel complement inhibitor limits severity of experimentally myasthenia gravis. Annals of neurology 65:67-75.
  25. Mans BJ, Ribeiro JM. Function, mechanism and evolution of the moubatin-clade of soft tick lipocalins. Insect Biochem Mol Biol. 2008 Sep;38(9):841-52.
  26. Roversi P., O. Lissina, S. Johnson, N. Ahmat, G. C. Paesen, K. Ploss, W. Boland, M. A. Nunn, and S. M. Lea. (2007). The structure of OMCI, a novel lipocalin inhibitor of the complement system. Journal of molecular biology 369:784-793.
  27. Hepburn, N. J., A. S. Williams, M. A. Nunn, J. C. Chamberlain-Banoub, J. Hamer, B. P. Morgan, and C. L. Harris. (2007). In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem 282:8292-8299.
  28. Nunn, M. A., A. Sharma, G. C. Paesen, S. Adamson, O. Lissina, A. C. Willis, and P. A. Nuttall. (2005). Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol 174:2084-2091.
  29. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, Kinoshita T, Kanakura Y. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014 Feb 13;370(7):632-9.